Sigyn Therapeutics EBITDA Growth & History (SIGY)

Sigyn Therapeutics's calculated EBITDA was −$2.4M for fiscal 2023.

View full Sigyn Therapeutics company overview

Sigyn Therapeutics annual ebitda history

Sigyn Therapeutics annual ebitda

Fiscal yearPeriod endedEBITDAChangeGrowth
20232023-12-31−$2.4M−$457,395
20212021-12-31−$2.0M−$1.1M
20202020-12-31−$905,134

Sigyn Therapeutics ebitda trends

Across the available reported history, Sigyn Therapeutics's ebitda decreased from −$2.0M to −$2.4M, a change of −$457,395. The latest reported quarter, Q4 2023, shows −$715,626.

About the metric

What EBITDA means

EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.

Calculation and source

How TickerStat calculates EBITDA

TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Sigyn Therapeutics filings at SEC.gov ↗